Skip to main content
FinSpry Logo
FinSpry
HRMY logo
HRMY
(NASDAQ)
Harmony Biosciences Holdings, Inc.
$27.74-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Harmony Biosciences Holdings (HRMY) Stock Price & Financial Analysis

Harmony Biosciences Holdings Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$27.21 - $27.84
52-Week High$40.87
52-Week Low$25.52
Open$27.44
Volume523.31K
Average Volume (3M)523.31K
Market Cap1.62B
Shares Outstanding58.54M
P/E Ratio (TTM)10.32
Forward P/E9.48
Price to Sales (P/S)1.88
Price to Book (P/B)1.88
EV/EBITDA4.41
Revenue (TTM)868.45M
Net Income (TTM)158.69M
Free Cash Flow (TTM)347.89M
EPS (TTM)$2.70
Profit Margin18.27%
Operating Margin24.00%
Return on Equity (ROE)18.24%
Debt to Equity0.28
50-Day MA$31.69
200-Day MA$33.29
52-Week Change-13.76%
Annual Dividend$0.00
Dividend Yield0.00%
Payout Ratio0.00%

Frequently Asked Questions About Harmony Biosciences Holdings

What is the current stock price for HRMY?

As of the latest trading session, HRMY stock trades at $27.74. The 52-week range is $25.52–$40.87, with a day range of $27.21–$27.84.

What is the P/E ratio for HRMY?

Harmony Biosciences Holdings's trailing P/E ratio is 10.3, meaning investors pay $10.3 for every $1 of annual earnings. The forward P/E is 9.5, reflecting analyst expectations for future earnings. Harmony Biosciences Holdings operates in the Healthcare sector.

Does HRMY pay dividends?

Harmony Biosciences Holdings does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for HRMY?

Based on 6 analysts, the consensus for HRMY is Buy. The average 12-month price target is $NaN, representing a NaN% downside from the current price.

What is the market cap of HRMY?

Harmony Biosciences Holdings's market capitalization is $1.62B, classifying it as a small-cap company. Harmony Biosciences Holdings operates in the Healthcare sector within the Biotechnology industry.